Published: 5 June 2021
Author(s): Dimitrios Patoulias, Athina Dimosiari, Theodoros Michailidis
Issue: August 2021
Section: Letter to the Editor

We have read with great interest the meta-analysis of observational studies performed by Pasin and colleagues [1] published in the European Journal of Internal Medicine, assessing the efficacy of anakinra, a recombinant interleukin-1 (IL-1) receptor antagonist, in patients with COVID-19 infection. The authors pooled data from 4 studies in a total of 184 patients, demonstrating that anakinra is superior to standard of care in terms of preventing COVID-19 related death, by reducing the corresponding risk by 74% [1].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.